Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase

Hyun Tae Kim, Byeong Kwan Na, Jiwoung Chung, Sulhee Kim, Sool Ki Kwon, Hyunju Cha, Jonghyeon Son, Joong Myung Cho, Kwang Yeon Hwang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Kynurenine 3-monooxygenase (KMO) inhibitors have been developed for the treatment of neurodegenerative disorders. The mechanisms of flavin reduction and hydrogen peroxide production by KMO inhibitors are unknown. Herein, we report the structure of human KMO and crystal structures of Saccharomyces cerevisiae (sc) and Pseudomonas fluorescens (pf) KMO with Ro 61-8048. Proton transfer in the hydrogen bond network triggers flavin reduction in p-hydroxybenzoate hydroxylase, but the mechanism triggering flavin reduction in KMO is different. Conformational changes via π-π interactions between the loop above the flavin and substrate or non-substrate effectors lead to disorder of the C-terminal α helix in scKMO and shifts of domain III in pfKMO, stimulating flavin reduction. Interestingly, Ro 61-8048 has two different binding modes. It acts as a competitive inhibitor in scKMO and as a non-substrate effector in pfKMO. These findings provide understanding of the catalytic cycle of KMO and insight for structure-based drug design of KMO inhibitors. KMO inhibitors have been developed for the treatment of neurodegenerative disorders, but the mechanisms of flavin reduction and H2O2 production by KMO inhibitors are unknown. Kim et al. propose the triggering mechanism of flavin reduction and reveal the cause of H2O2 production by the inhibitors in KMO.

Original languageEnglish
JournalCell Chemical Biology
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Kynurenine 3-Monooxygenase
Hydrogen Peroxide
Neurodegenerative Diseases
4-Hydroxybenzoate-3-Monooxygenase
Pseudomonas fluorescens
Proton transfer
Drug Design
4,6-dinitro-o-cresol
Yeast
Saccharomyces cerevisiae
Protons
Hydrogen

Keywords

  • Drug design
  • Flavin reduction
  • Hydrogen peroxide
  • KMO inhibitor
  • Kynurenine 3-monooxygenase

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase. / Kim, Hyun Tae; Na, Byeong Kwan; Chung, Jiwoung; Kim, Sulhee; Kwon, Sool Ki; Cha, Hyunju; Son, Jonghyeon; Cho, Joong Myung; Hwang, Kwang Yeon.

In: Cell Chemical Biology, 01.01.2018.

Research output: Contribution to journalArticle

Kim, Hyun Tae ; Na, Byeong Kwan ; Chung, Jiwoung ; Kim, Sulhee ; Kwon, Sool Ki ; Cha, Hyunju ; Son, Jonghyeon ; Cho, Joong Myung ; Hwang, Kwang Yeon. / Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase. In: Cell Chemical Biology. 2018.
@article{a9c76314650344b89d2135ebef08f452,
title = "Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase",
abstract = "Kynurenine 3-monooxygenase (KMO) inhibitors have been developed for the treatment of neurodegenerative disorders. The mechanisms of flavin reduction and hydrogen peroxide production by KMO inhibitors are unknown. Herein, we report the structure of human KMO and crystal structures of Saccharomyces cerevisiae (sc) and Pseudomonas fluorescens (pf) KMO with Ro 61-8048. Proton transfer in the hydrogen bond network triggers flavin reduction in p-hydroxybenzoate hydroxylase, but the mechanism triggering flavin reduction in KMO is different. Conformational changes via π-π interactions between the loop above the flavin and substrate or non-substrate effectors lead to disorder of the C-terminal α helix in scKMO and shifts of domain III in pfKMO, stimulating flavin reduction. Interestingly, Ro 61-8048 has two different binding modes. It acts as a competitive inhibitor in scKMO and as a non-substrate effector in pfKMO. These findings provide understanding of the catalytic cycle of KMO and insight for structure-based drug design of KMO inhibitors. KMO inhibitors have been developed for the treatment of neurodegenerative disorders, but the mechanisms of flavin reduction and H2O2 production by KMO inhibitors are unknown. Kim et al. propose the triggering mechanism of flavin reduction and reveal the cause of H2O2 production by the inhibitors in KMO.",
keywords = "Drug design, Flavin reduction, Hydrogen peroxide, KMO inhibitor, Kynurenine 3-monooxygenase",
author = "Kim, {Hyun Tae} and Na, {Byeong Kwan} and Jiwoung Chung and Sulhee Kim and Kwon, {Sool Ki} and Hyunju Cha and Jonghyeon Son and Cho, {Joong Myung} and Hwang, {Kwang Yeon}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.chembiol.2018.01.008",
language = "English",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase

AU - Kim, Hyun Tae

AU - Na, Byeong Kwan

AU - Chung, Jiwoung

AU - Kim, Sulhee

AU - Kwon, Sool Ki

AU - Cha, Hyunju

AU - Son, Jonghyeon

AU - Cho, Joong Myung

AU - Hwang, Kwang Yeon

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Kynurenine 3-monooxygenase (KMO) inhibitors have been developed for the treatment of neurodegenerative disorders. The mechanisms of flavin reduction and hydrogen peroxide production by KMO inhibitors are unknown. Herein, we report the structure of human KMO and crystal structures of Saccharomyces cerevisiae (sc) and Pseudomonas fluorescens (pf) KMO with Ro 61-8048. Proton transfer in the hydrogen bond network triggers flavin reduction in p-hydroxybenzoate hydroxylase, but the mechanism triggering flavin reduction in KMO is different. Conformational changes via π-π interactions between the loop above the flavin and substrate or non-substrate effectors lead to disorder of the C-terminal α helix in scKMO and shifts of domain III in pfKMO, stimulating flavin reduction. Interestingly, Ro 61-8048 has two different binding modes. It acts as a competitive inhibitor in scKMO and as a non-substrate effector in pfKMO. These findings provide understanding of the catalytic cycle of KMO and insight for structure-based drug design of KMO inhibitors. KMO inhibitors have been developed for the treatment of neurodegenerative disorders, but the mechanisms of flavin reduction and H2O2 production by KMO inhibitors are unknown. Kim et al. propose the triggering mechanism of flavin reduction and reveal the cause of H2O2 production by the inhibitors in KMO.

AB - Kynurenine 3-monooxygenase (KMO) inhibitors have been developed for the treatment of neurodegenerative disorders. The mechanisms of flavin reduction and hydrogen peroxide production by KMO inhibitors are unknown. Herein, we report the structure of human KMO and crystal structures of Saccharomyces cerevisiae (sc) and Pseudomonas fluorescens (pf) KMO with Ro 61-8048. Proton transfer in the hydrogen bond network triggers flavin reduction in p-hydroxybenzoate hydroxylase, but the mechanism triggering flavin reduction in KMO is different. Conformational changes via π-π interactions between the loop above the flavin and substrate or non-substrate effectors lead to disorder of the C-terminal α helix in scKMO and shifts of domain III in pfKMO, stimulating flavin reduction. Interestingly, Ro 61-8048 has two different binding modes. It acts as a competitive inhibitor in scKMO and as a non-substrate effector in pfKMO. These findings provide understanding of the catalytic cycle of KMO and insight for structure-based drug design of KMO inhibitors. KMO inhibitors have been developed for the treatment of neurodegenerative disorders, but the mechanisms of flavin reduction and H2O2 production by KMO inhibitors are unknown. Kim et al. propose the triggering mechanism of flavin reduction and reveal the cause of H2O2 production by the inhibitors in KMO.

KW - Drug design

KW - Flavin reduction

KW - Hydrogen peroxide

KW - KMO inhibitor

KW - Kynurenine 3-monooxygenase

UR - http://www.scopus.com/inward/record.url?scp=85041687575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041687575&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2018.01.008

DO - 10.1016/j.chembiol.2018.01.008

M3 - Article

C2 - 29429898

AN - SCOPUS:85041687575

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

ER -